Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2002-10-25
2009-06-09
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S721000, C514S731000
Reexamination Certificate
active
07544674
ABSTRACT:
A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
REFERENCES:
patent: 1429430 (1922-10-01), Holmes et al.
patent: 2164723 (1939-07-01), Schrauth et al.
patent: 3226295 (1965-12-01), Goetz et al.
patent: 3776857 (1973-12-01), Lindner
patent: 3856934 (1974-12-01), Kligman
patent: 3906108 (1975-09-01), Felty
patent: 3966924 (1976-06-01), Fredriksson
patent: 4146499 (1979-03-01), Rosano
patent: 4254104 (1981-03-01), Suzuki
patent: 4427670 (1984-01-01), Ofuchi et al.
patent: 4603046 (1986-07-01), Georgalas et al.
patent: 4603146 (1986-07-01), Kligman
patent: 4654373 (1987-03-01), Bertelli
patent: 4737360 (1988-04-01), Allen et al.
patent: 4857321 (1989-08-01), Thomas
patent: 4992478 (1991-02-01), Geria
patent: 5145604 (1992-09-01), Neumiller
patent: 5514698 (1996-05-01), Ahmad et al.
patent: 5538737 (1996-07-01), Leonard et al.
patent: 5573781 (1996-11-01), Brown et al.
patent: 5626873 (1997-05-01), Weiner et al.
patent: 5645854 (1997-07-01), Masiz
patent: 5651991 (1997-07-01), Sugiyama et al.
patent: 5656672 (1997-08-01), Collin et al.
patent: 5660837 (1997-08-01), Lundquist
patent: 5744148 (1998-04-01), Habif et al.
patent: 5851543 (1998-12-01), Korb et al.
patent: 5935589 (1999-08-01), Mulcherjee et al.
patent: 5951993 (1999-09-01), Scholz et al.
patent: 5962512 (1999-10-01), Goupil
patent: 5976555 (1999-11-01), Liu et al.
patent: 5997890 (1999-12-01), Sine et al.
patent: 6001377 (1999-12-01), SaNogueira, Jr. et al.
patent: 6030623 (2000-02-01), Meade
patent: 6080393 (2000-06-01), Liu et al.
patent: 6090395 (2000-07-01), Asmus et al.
patent: 6139824 (2000-10-01), Ribery et al.
patent: 6153657 (2000-11-01), Kisuno et al.
patent: 6174533 (2001-01-01), SaNogueira, Jr. et al.
patent: 6200964 (2001-03-01), Singleton et al.
patent: 6267985 (2001-07-01), Chen et al.
patent: 6365656 (2002-04-01), Green et al.
patent: 6383499 (2002-05-01), Lipi
patent: 6413536 (2002-07-01), Gibson
patent: 6423323 (2002-07-01), Neubourg
patent: 2005/0101580 (2005-05-01), Puglia et al.
patent: 2006/0099173 (2006-05-01), Puglia et al.
patent: 01-203036 (1989-08-01), None
patent: 1999-0087346 (1999-12-01), None
patent: 2000-0073077 (2000-12-01), None
patent: 2001-0089781 (2001-10-01), None
patent: WO-03/055472 (2003-07-01), None
patent: WO-2004/021967 (2004-03-01), None
patent: WO 2004/037201 (2004-05-01), None
FDA, Tri-Luma™ approval letter (Jan. 18, 2002).
Galderma Laboratories, Tri-Luma™ prescribing information (Jan. 2002).
PCT International Search Report dated Aug. 27, 2004.
Lack et al., New Eng J Med, 348(11):977-85 (2003).
Lever, B Med J, 313:299-300 (1996).
Taylor et al., J Allergy Clin Immunol, 68(5):372-75 (1981).
Gilbert, B., “TriLuma Combination Effective For PIH”, Determatology Times, Sep. 1, 2005, pp. 1-2 (XP-002403792).
Cook-Bolden, F. et al., “The Use Of A Triple-Drug Combination Product and Procedures For The Treatment Of Hyperpigmentary Disorders”, Cosmetic Dermatology, vol. 18, No. 8, pp. 589-594 (XP009066078).
Callender, V.D., “Acne In Ethnic Skin: Special Considerations For Therapy”, Dermatologic Therapy, 2004 No. 2, vol. 17, pp. 184-195, Blackwell Publishing, Inc., US (XP-002383242).
Goodheart, H.P., “Hyperpigmentation Disorders”, Women's Health In Primary Care, vol. 2, No. 12, Dec. 1999, pp. 923, 924, 929 (XP-002251799).
Momosawa, A. et al., “Combined Therapy Using Q-Switched Ruby Laser And Bleaching Treatment With Tretinoin And Hydroquinone For acquired Dermal Melanocytosis”, Dermatologic Surgery, Oct. 1, 2003, vol. 29, No. 10, pp. 1001-1007; Blackwell Publishing, Inc., US (XP-002383243).
Clark, J., “Cream Combo Called Melasma Drug Of Chorice”, Dermatology Times, vol. 23 No. 5, May 1, 2002, pp. 1-2 (XP008062911).
Mosby, C.V., Journal Of The American Academy Of Dermatology, vol. 52, No. 3, Mar. 2005, p. 19.
Katsambas, A.D. et al., “Depigmenting and Bleaching Agents: coping With Hyperpigmentation”, Clinics in Dermatology, vol. 19, 2001, pp. 483-488, Elsevier Science B.V.
Kang, S. et al., “Assessment Of Adapalene Gel For The Treatment Of Actinic Keratoses And Lentigines: A Randomized Trial”, Journal Of The American Academy Of Dermatology, Jul. 2003, vol. 49, No. 1, pp. 83-90.
Milikan, L.E., “Adapalene: An Update On Newei Comparative Studies Between The Various Retinoids”, International Journal of Dermatology, vol. 39, No. 10, 2000, pp. 784-788.
Gollnick, H. et al., “Topical Therapy In Acne”, Journal Of European Academy Of Dermatology and Venereology, vol. 11, No. Supp. 1, Sep. 1998, pp. S08-S12, Elsevier Science B.V.
Torok, H.M., Hydroquinone 4%, Tretinoin 0.05%, Fluocinolone Acetonide 0.01%, Flucinolone Acetonide 0.01%: A Safe And Efficacious 12-Month Treatment For Melasma et al., Therapeutics For Clinician, vol. 75, No. 1, Jan. 2005, pp. 57-62.
Puglia Nancy
Ramirez Rosario
Roth Jerry
Claytor Renee
Darby & Darby P.C.
Galderma S.A.
Padmanabhan Sreeni
LandOfFree
Topical skin care composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical skin care composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical skin care composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4066765